NK cell receptor and tumor antigen interface

The NK cell receptor and tumor antigen interface, also known as the immunological synapse, is the dynamic physical junction where Natural Killer (NK) cells interact with potential target cells, such as tumor cells (Orange et al., 2008, Nature Reviews Immunology). This interface is governed by a "rheostat" model, where the integration of signals from a diverse array of activating receptors (e.g., NKG2D, CD16, DNAM-1) and inhibitory receptors (e.g., KIRs, NKG2A, TIGIT) determines the NK cell's effector response (Long et al., 2013, Annual Review of Immunology). In the context of cancer, tumor cells often exploit this interface by upregulating inhibitory ligands (like HLA-E or PD-L1) or shedding activating ligands (like MICA/B) to evade immune detection (Shimasaki et al., 2020, Nature Reviews Drug Discovery). Therapeutic interventions targeting this interface include monoclonal antibodies that block inhibitory checkpoints (e.g., Monalizumab targeting NKG2A) and bi-specific or tri-specific killer cell engagers (BiKEs/TriKEs) that physically bridge NK cells to tumor antigens to trigger potent cytotoxicity (Felices et al., 2016, Biology of Blood and Marrow Transplantation). Understanding the molecular architecture of this interface is critical for developing next-generation immunotherapies, including CAR-NK cells and cytokine-augmented treatments that enhance NK cell persistence and activity within the tumor microenvironment.

Other names

NK cell immunological synapseNK-tumor cell interfaceNK cell-target cell contact siteNK cell immune synapse

Enhancement of NK cell-mediated tumor lysis by blocking inhibitory receptor-ligand interactions (checkpoints) or cross-linking activating receptors to tumor-associated antigens (Shimasaki et al., 2020, Nature Reviews Drug Discovery).